

## Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



3 1 OCT 2018

TO:

**GENERAL CONSUMING PUBLIC** 

SUBJECT:

Amendment to FDA Advisory No. 2018-274 "Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 10)" Dated 10 September 2018

The Food and Drug Administration (FDA) hereby advises the public that the cosmetic products listed in FDA Advisory No. 2018-274 "Public Health Warning Against the Use of Cosmetic Products Containing Banned Ingredient/s (Batch 10)" dated 10 September 2018 is amended to remove the products, SKINWHITE® POWERWHITENING® WHITENING LOTION INSTANT WHITE SPF 20 and SKINWHITE® POWERWHITENING® WHITENING LOTION KOJIC ACID SPF 20.

After coordination with the Market Authorization Holder (MAH), Splash Corporation, FDA has determined that the aforementioned cosmetic products are now compliant with the existing FDA rules, regulations and standards and has been issued the appropriate market authorization with the following details:

Brand Name

**SKINWHITE®** 

Product Name

**SKINWHITE®** 

POWER WHITENING ®
WHITENING LOTION
INSTANT WHITE SPF 20

Notification Number

NN-10000001521116

Validity

17 March 2021

Market Authorization:

Splash Corporation

Holder

Holder

DL '1'

Country of Manufacture

Philippines

Brand Name

: SKINWHITE®

Product Name

: POWERWHITENING®

WHITENING LOTION KOJIC

ACID SPF 20

Notification Number

: NN-1000001519799

Validity

10 January 2021

Market Authorization

Splash Corporation

Holder

Country of

Philippines

Manufacture



SkinWhite









The MAH is urged to strictly comply with FDA implemented laws, rules and regulations and to closely monitor the marketing of the subject products. Nothing in this Advisory shall preclude the FDA from pursuing further actions, as it may deem necessary, against the MAH, should the subject products, be confirmed to contain banned ingredients.

In view thereof, FDA Advisory No. 2018-274 is hereby updated accordingly. For more information and inquiries, please e-mail us at <a href="info@fda.gov.ph">info@fda.gov.ph</a>. To report any suspicious activity and/or product, kindly e-mail us via <a href="report@fda.gov.ph">report@fda.gov.ph</a>, call us at the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 857-1900 local 8113/8017, or utilize our online reporting facility, eReport, at <a href="www.fda.gov.ph/ereport">www.fda.gov.ph/ereport</a>.

Dissemination of the information to all concerned is requested

NELA CHARADE G. PUNO, RPI

Director General

DTN 20181019155003